Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$135.41 USD
-1.25 (-0.91%)
Updated May 31, 2024 04:00 PM ET
After-Market: $135.49 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 61 - 80 ( 307 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Beat And Raise For 2Q22 Driven By Ingrezza Strength
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Weekly Neurology Prescription Sales Tracker -- Week Ending 7/29/22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Weekly Neurology Prescription Sales Tracker - Week Ending 6/17/22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Weekly Neurology Prescription Sales Tracker - Week Ending 5/27/22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
How to Think About NBI-827104?s Upcoming Data Readout in Mid 2022?
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Commercial Execution On Display in 1Q22 With Ingrezza Beat
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
1Q22 Commercial Biotech Preview: Let''s Get It Over With
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Weekly Neurology Prescription Sales Tracker -- Week Ending 3/11/22
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Weekly Neurology Prescription Sales Tracker -- Week Ending 3/4/22
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Amidst Strong 2022 Guidance, We Focus on NBI-827104 in ET; Reit BUY and $140 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Weekly Neurology Prescription Sales Tracker -- Week Ending 2/4/22
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Solid FY22 Guide As Market Dynamics Appear Favorable
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Considerations for New Pipeline Dynamics; Phase 2 Catalysts in Near-Term
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
4Q21 Commercial Biotech Preview: Getting The Ducks In A Row
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Weekly Neurology Prescription Sales Tracker -- Week Ending 1/14/22
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Weekly Neurology Prescription Sales Tracker -- Week Ending 1/7/22
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Ingrezza Gains Ground Despite Pandemic; Our Focus on Near-Term Catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A